DWP-450 is a 900 kDa botulinum toxin type A produced by Clostridium botulinum.
METHODS:
Study subjects were at least 18 years of age and had moderate (GLS=2) to severe (GLS=3) glabellar lines at maximum frown, on the 4-point photonumeric Glabellar Line Scale (GLS, 0=no lines, 1=mild, 2=moderate, 3=severe). Subjects were randomly assigned in a 3:1 ratio to receive a single treatment (0.1 mL injected into each of 5 target sites in the glabellar region) of either DWP-450 (total of 20 U, administered as 4 U/0.1 mL) or Placebo (0.9% saline). Subjects were then followed for 150 days. The primary efficacy endpoint was defined as the proportion of subjects classified as responders on Day 30. This was a composite endpoint based on both the Investigator and subject's assessments of glabellar lines at maximum frown on the GLS; a subject was a responder only if both independently agreed that a ≥2 point improvement had occurred from Day 0 to Day 30. Safety was evaluated throughout the study.
RESULTS: 330 subjects participated in the EV-001 study; 324 participated in EV-002.
For the primary efficacy endpoint, in EV-001 and EV-002 the percentages of responders in each of the Placebo and DWP-450 groups were 1.2% and 67.5%, and 1.3% and 70.4% respectively; the absolute difference between groups was 66.3% (p<0.001) and 69.1%(p<0.001) respectively.
Also at Day 30, as assessed by the Investigator using the Global Aesthetic Improvement Scale, in EV-001 and EV-002 the proportion of responders was 95.8% and 92.9% respectively.
In total, for each of EV-001 and EV-002: 38.2% of DWP-450 subjects and 32.1% of Placebo subjects, and 28.5% of DWP-450 subjects and 26.9% of Placebo subjects respectively, experienced one or more adverse events.
CONCLUSION:
The results of these two parallel US phase III studies successfully met the predefined primary endpoint. 1,2 Knowledge about any potential adverse event, including alopecia, is important for informed consent and setting patient expectations. This study is the first to characterize alopecia in patients undergoing deoxycholic acid treatment for submental fat.
Alopecia in Male Patients

METHODS:
A retrospective review was conducted of 171 patients (66 male) treated with deoxycholic acid in the submental region at a single-center between January 2015-December 2016. Deoxycholic acid was injected into the preplatysmal submental fat (0.2 mL per injection of 10mg/mL to achieve a dose of 2mg/cm 2 ) for a maximum of 6 treatments. Patient characteristics, treatment plan, and severity/resolution of alopecia was analyzed.
RESULTS:
Alopecia was reported in 15% of male patients (none observed in female patients). Severity of alopecia in follow-up patients (n=8) ranged from diffuse/mild to 6 patches of alopecia, and was not associated with dose delivered or number of injections. Alopecia was noticed a median 31.5 days after injection (range 15-94 days). Five of eight patients reported improvement or complete resolution of alopecia. Six of eight patients experienced alopecia after the first treatment. Five of eight patients seeked further treatment despite alopecia.
CONCLUSION:
Alopecia is a real adverse event following treatment of deoxycholic acid for submental fat reduction in males that occurs approximately 1 month after treatment. Severity is not dependent on treatment plan, and is likely due to PSTM 2017 Abstract Supplement Monday, October 9, 2017 patient characteristics. While a majority of patients had improvement or resolution, longer follow-up is needed to further assess the transiency of injection-induced alopecia. Importantly, a majority of patients continued to seek further treatment, suggesting patient-impact of this alopecia was low compared to the benefits of submental fat reduction.
